DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2008/0045488 A1 RODRGUEZ (43) Pub

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2008/0045488 A1 RODRGUEZ (43) Pub US 20080045488A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2008/0045488 A1 RODRGUEZ (43) Pub. Date: Feb. 21, 2008 (54) PREVENTION OF OVARIAN CANCER BY Continuation-in-part of application No. 09/528,963, ADMINISTRATION OF PRODUCTS THAT filed on Mar. 21, 2000, now Pat. No. 6,765,002. INDUCE BIOLOGICAL EFFECTS IN THE Continuation-in-part of application No. 09/672,735, OVARIAN EPTHELIUM filed on Sep. 28, 2000, now Pat. No. 6.511,970. Continuation-in-part of application No. 09/532,340, (75) Inventor: Gustavo C. RODRIGUEZ, Durham, filed on Mar. 21, 2000, now abandoned. NC (US) Publication Classification Correspondence Address: JENNER & BLOCK, LLP (51) Int. Cl. ONE IBM PLAZA A6II 3/56 (2006.01) A 6LX 3/57 (2006.01) CHICAGO, IL 60611 (US) A6IP 35/00 (2006.01) (73) Assignee: New Life Pharmaceuticals Inc., Chi (52) U.S. Cl. ............................................ 514/171; 514/178 cago, IL (US) (57) ABSTRACT The present invention relates to compositions and methods (21) Appl. No.: 11/771,473 for preventing the development of epithelial ovarian cancer (22) Filed: Jun. 29, 2007 by administering compounds in an amount capable of regu lating TGF-B expression in the ovarian epithelium and/or Related U.S. Application Data capable of optimally altering expression of other Surrogate biomarkers identified by microarray technology. HRT and (63) Continuation of application No. 09/798,453, filed on OCP regimens comprising such compositions and methods Mar. 2, 2001. are disclosed. US 2008/0045488 A1 Feb. 21, 2008 PREVENTION OF OVARAN CANCER BY have been thought to increase ovarian cancer risk, whereas ADMINISTRATION OF PRODUCTS THAT INDUCE Some factors that Suppress ovulation have been thought to BIOLOGICAL EFFECTS IN THE OVARAN decrease risk. Chapter 21, Ovarian Cancer, Harrison's EPTHELUM Principles of Internal Medicine. These data have led to the 0001. This application is a continuation of Ser. No. “incessant ovulation” hypothesis for the development of 09/798,453 filed Mar. 2, 2001, which is a continuation-in ovarian cancer. Casagrande et al., Incessant Ovulation and part of U.S. Ser. No. 09/528,963 filed Mar. 21, 2000 (now Ovarian Cancer, Lancet at 170-73 (Jul. 28, 1979). This U.S. Pat. No. 6,765,002) and is also a continuation-in-part of hypothesis is that repeated ovulation cycles, each of which application Ser. No. 09/672,735, filed Sep. 28, 2000 (now involves the disruption and repair of the ovarian surface U.S. Pat. No. 6.511,970) which is a continuation-in-part of epithelium, may cause neoplastic transformation of the application Ser. No. 09/532,340 filed Mar. 21, 2000 (now ovarian epithelium in susceptible individuals and that the abandoned). risk of ovarian cancer is positively associated with the number of ovulation cycles in a woman’s lifetime. FIELD OF THE INVENTION 0005 The reduction in risk of ovarian cancer in women 0002 The present invention relates generally to methods who have used estrogen-progestin combination oral contra of preventing or reducing the risk of the development of ceptives for at least three years is approximately 40 percent. ovarian cancer by pharmacological approaches available to Moreover, this protective effect increases with the duration women of all ages. of use and persists for up to two decades after discontinu ation of use. Rosenberg et al., A Case Control Study of Oral BACKGROUND OF THE INVENTION Contraceptive Use and Invasive Epithelial Ovarian Cancer, 0003 Epithelial ovarian cancer is seldom encountered in The WHO Collaborative Study of Neoplasia and Steroid women less than 35 years of age. Its incidence increases Contraceptives, Epithelial Ovarian Cancer and Combined sharply with advancing age and peaks at ages 75 to 80, with Oral Contraceptives, Int'l J. Epidemiology 18: 538-45, the median age being 60 years. The single most important 1989; Lee et al., The Reduction in Risk of Ovarian Cancer risk factor for this cancer is a strong family history of breast Associated with Oral Contraceptive Use, New Engl. J. Med. or ovarian cancer. Oncogenes associated with ovarian can 316: 650-51, 1987: Thomas P. Gross, James J. Schlesselman, cers include the HER-2/neu (c-erbB-2) oncogene, which is overexpressed in a third of ovarian cancers, the fms onco The Estimated Effect of Oral Contraceptive Use on the gene, and abnormalities in the p53 gene, which are seen in Cumulative Risk of Epithelial Ovarian Cancer, Obstetrics about half of ovarian cancers. A number of environmental Gynecology 83: 419-24, 1994; Franceschi et al., Pooled factors have also been associated with a higher risk of Analysis of 3 European Case-Control Studies of Epithelial epithelial ovarian cancer, including a high fat diet and intake Ovarian Cancer. III. Oral Contraceptive Use, Int'l J. Can of lactose in subjects with relatively low tissue levels of cer 49: 61-65, 1991. galactose-1-phosphate uridyl transferase. 0006. It was commonly believed that the protective effect 0004. In epidemiological studies, behaviors associated of oral contraceptives is related to the ability of these drugs with decreased ovulation, Such as pregnancy, breastfeeding to inhibit ovulation. Estrogen-progestin combination oral and use of estrogen-progestin combination oral contracep contraceptives act primarily by Suppressing the pituitary tive medications, decrease the risk of ovarian cancer, use of gland's production of gonadotropins, thereby inhibiting the estrogen-progestin combination oral contraceptives for as hormonal stimulus for ovulation. These combination drugs long as 5 years can reduce the risk of ovarian cancer by 50%. also have direct inhibitory effects on the reproductive tract, Greene et al., The Epidemiology of Ovarian Cancer, Semi including inducing changes in the cervical mucus that nars Oncology, 11: 209-225, 1984: Whitmore et al., Char decrease the ability of sperm to enter the uterus, as well as acteristics Relating To Ovarian Cancer Risk Collaborative changes in the endometrium that reduce the likelihood of Analysis of 12 US Case-Control Studies, American J. Epi implantation, and reducing fallopian tube motility and uter demiology 136: 1212-20, 1992. Conversely, early menarche, ine secretions. late menopause and nulliparity (no pregnancies) have been shown to increase the risk of ovarian cancer. The risk has 0007. The epidemiological studies showing the protec been shown to positively correlate with the number of tive effect of combination oral contraceptives evaluated ovulatory cycles in a woman’s lifetime. Wu et al., Personal older combination preparations which typically contained and Environmental Characteristics Related To Epithelial higher doses of drug than most contraceptive regimens used Ovarian Cancer, American J. Epidemiology, Vol. 108(6) today. Common older regimens contained 50 micrograms or 1216-1227. The long-term use of ovulation-inducing ova more of ethinyl estradiol (an estrogen) or 100 micrograms or rian hyperstimulants such as clomiphene has been shown to more of mestranol (an estrogen) and greater than 1 mg of be associated with an increased risk of ovarian cancer in norethindrone, norethindrone acetate or norethynodrel some women. Rossary et al., Ovarian Tumors in a Cohort Of (progestins). Various combinations of progestin and estro Infertile Women, New Engl. J. Med., 331: 771-6, 1994. Thus, gen that have been used in oral contraceptives are shown in Some factors that favor prolonged and persistent ovulation Table 1. US 2008/0045488 A1 Feb. 21, 2008 TABLE 1. Trends In Combinations of Progestin and Estrogen Norethindrone Dose Equivalent Dose EE Equivalent Progestin (mg) Dose(mg) Estrogen (mg) Dose(mg) PE Ratio Norethynodrel 9.85 9.85 Mestranol O.1SO O.1OS 93.810 S.OO S.OO 0.075 O.OS3 95.238 2.50 2.50 O.036 O.O2S 99.2O6 2.50 2.50 O.100 O.O70 35.714 Norethindrone 10.00 10.00 Mestranol O.O60 O.042 238.095 2.OO 2.00 O.100 O.O70 28.571 1.OO OO O.OSO O.O3S 28.571 1.OO OO O.O8O O.OS6 17.857 Norethindrone 1.OO OO Ethinyl O.OSO O.OSO 2O.OOO OSO O.SO estradiol (EE) 0.035 O.O3S 14.286 O4O O.40 O.O3S O.O3S 11.429 Norethindrone 2.50 2.50 EE O.OSO O.OSO SO.OOO acetate 1.OO OO O.OSO O.OSO 2O.OOO O.6O O.60 O.O3O O.O3O 2O.OOO 1...SO SO O.O3O O.O3O SO.OOO 1.OO OO O.O2O O.O2O SO.OOO Ethynodiol 1.OO OO Mestranol O.100 O.O70 14.286 diacetate Ethynodiol 1.OO OO EE O.OSO O.OSO 2O.OOO diacetate dl-Norgestrel OSO 2.00 EE O.OSO O.OSO 1O.OOO O.30 2O O.O3O O.O3O 1O.OOO Equivalencies 50 mg Mestranol = 35 mg Ethinyl estradiol (EE) 0.5 mg di-Norgestrel = 2 mg Norethindrone Each block describes a specific combination of progestin and estrogen, e.g., norethynodrel and mestranol, and within TABLE 2-continued each block older combinations are listed first, with succes sively newer combinations following. Two trends are evi Composition of Selected Currently Marketed Oral Contraceptives dent. First, over time the dosage of each component has Mg decreased. Second, the downward trend of the progestin 19. component is steeper than the downward trend of the Estrogen content <50 9. estrogen component. On a relative scale, therefore, estrogen Ortho-Novum 135 Ethinyl estradio 35 Norethindrone 1.O has become more important over time. With this downward Norinyl 1 + 35 Ethinyl estradio 35 Norethindrone 1.O trend in dosage, it is apparent that the relative ratio of Modicon Ethinyl estradio 35 Norethindrone O.S progestin to estrogen is trending downward. Brevicon Ethinyl estradio 35 Norethindrone O.S Owcom 35 Ethinyl estradio 35 Norethindrone 0.4 0008 All of the currently used low-dose combination Demulen 1.35 Ethinyl estradio 35 Ethynodiol diacetate 1.O Loestrin 1.5.30 Ethinyl estradio 30 Norethindrone 1.5 oral contraceptives contain lower doses of both progestin acetate and estrogen, as well as a lower ratio of progestin to Loestrin 120 Ethinyl estradio 20 Norethindrone 1.O estrogen.
Load more

Recommended publications
  • (CD-P-PH/PHO) Report Classification/Justifica
    COMMITTEE OF EXPERTS ON THE CLASSIFICATION OF MEDICINES AS REGARDS THEIR SUPPLY (CD-P-PH/PHO) Report classification/justification of medicines belonging to the ATC group D07A (Corticosteroids, Plain) Table of Contents Page INTRODUCTION 4 DISCLAIMER 6 GLOSSARY OF TERMS USED IN THIS DOCUMENT 7 ACTIVE SUBSTANCES Methylprednisolone (ATC: D07AA01) 8 Hydrocortisone (ATC: D07AA02) 9 Prednisolone (ATC: D07AA03) 11 Clobetasone (ATC: D07AB01) 13 Hydrocortisone butyrate (ATC: D07AB02) 16 Flumetasone (ATC: D07AB03) 18 Fluocortin (ATC: D07AB04) 21 Fluperolone (ATC: D07AB05) 22 Fluorometholone (ATC: D07AB06) 23 Fluprednidene (ATC: D07AB07) 24 Desonide (ATC: D07AB08) 25 Triamcinolone (ATC: D07AB09) 27 Alclometasone (ATC: D07AB10) 29 Hydrocortisone buteprate (ATC: D07AB11) 31 Dexamethasone (ATC: D07AB19) 32 Clocortolone (ATC: D07AB21) 34 Combinations of Corticosteroids (ATC: D07AB30) 35 Betamethasone (ATC: D07AC01) 36 Fluclorolone (ATC: D07AC02) 39 Desoximetasone (ATC: D07AC03) 40 Fluocinolone Acetonide (ATC: D07AC04) 43 Fluocortolone (ATC: D07AC05) 46 2 Diflucortolone (ATC: D07AC06) 47 Fludroxycortide (ATC: D07AC07) 50 Fluocinonide (ATC: D07AC08) 51 Budesonide (ATC: D07AC09) 54 Diflorasone (ATC: D07AC10) 55 Amcinonide (ATC: D07AC11) 56 Halometasone (ATC: D07AC12) 57 Mometasone (ATC: D07AC13) 58 Methylprednisolone Aceponate (ATC: D07AC14) 62 Beclometasone (ATC: D07AC15) 65 Hydrocortisone Aceponate (ATC: D07AC16) 68 Fluticasone (ATC: D07AC17) 69 Prednicarbate (ATC: D07AC18) 73 Difluprednate (ATC: D07AC19) 76 Ulobetasol (ATC: D07AC21) 77 Clobetasol (ATC: D07AD01) 78 Halcinonide (ATC: D07AD02) 81 LIST OF AUTHORS 82 3 INTRODUCTION The availability of medicines with or without a medical prescription has implications on patient safety, accessibility of medicines to patients and responsible management of healthcare expenditure. The decision on prescription status and related supply conditions is a core competency of national health authorities.
    [Show full text]
  • A New Robust Technique for Testing of Glucocorticosteroids in Dogs and Horses Terry E
    Iowa State University Capstones, Theses and Retrospective Theses and Dissertations Dissertations 2007 A new robust technique for testing of glucocorticosteroids in dogs and horses Terry E. Webster Iowa State University Follow this and additional works at: https://lib.dr.iastate.edu/rtd Part of the Veterinary Toxicology and Pharmacology Commons Recommended Citation Webster, Terry E., "A new robust technique for testing of glucocorticosteroids in dogs and horses" (2007). Retrospective Theses and Dissertations. 15029. https://lib.dr.iastate.edu/rtd/15029 This Thesis is brought to you for free and open access by the Iowa State University Capstones, Theses and Dissertations at Iowa State University Digital Repository. It has been accepted for inclusion in Retrospective Theses and Dissertations by an authorized administrator of Iowa State University Digital Repository. For more information, please contact [email protected]. A new robust technique for testing of glucocorticosteroids in dogs and horses by Terry E. Webster A thesis submitted to the graduate faculty in partial fulfillment of the requirements for the degree of MASTER OF SCIENCE Major: Toxicology Program o f Study Committee: Walter G. Hyde, Major Professor Steve Ensley Thomas Isenhart Iowa State University Ames, Iowa 2007 Copyright © Terry Edward Webster, 2007. All rights reserved UMI Number: 1446027 Copyright 2007 by Webster, Terry E. All rights reserved. UMI Microform 1446027 Copyright 2007 by ProQuest Information and Learning Company. All rights reserved. This microform edition is protected against unauthorized copying under Title 17, United States Code. ProQuest Information and Learning Company 300 North Zeeb Road P.O. Box 1346 Ann Arbor, MI 48106-1346 ii DEDICATION I want to dedicate this project to my wife, Jackie, and my children, Shauna, Luke and Jake for their patience and understanding without which this project would not have been possible.
    [Show full text]
  • Pre - PA Allowance Age 18 Years of Age Or Older Quantity 60 Grams Every 90 Days ______
    DOXEPIN CREAM 5% (Prudoxin, Zonalon) Pre - PA Allowance Age 18 years of age or older Quantity 60 grams every 90 days _______________________________________________________________ Prior-Approval Requirements Age 18 years of age or older Diagnosis Patient must have the following: Moderate pruritus, due to atopic dermatitis (eczema) or lichen simplex chronicus AND the following: 1. Inadequate response, intolerance or contraindication to ONE medication in EACH of the following categories: a. Topical antihistamine (see Appendix I) b. High potency topical corticosteroid (see Appendix II) 2. Physician agrees to taper patient’s dose to the FDA recommended dose, and after tapered will only use for short-term pruritus relief (up to 8 days) a. Patients using over 60 grams of topical doxepin in 90 days be required to taper to 60 grams topical doxepin within 90 days Prior - Approval Limits Quantity 180 grams for 90 days Duration 3 months ___________________________________________________________________ Prior – Approval Renewal Requirements None (see appendix below) Doxepin 5% cream FEP Clinical Rationale DOXEPIN CREAM 5% (Prudoxin, Zonalon) APPENDIX I Drug Dosage Form Diphenhydramine Cream Phenyltoloxamine Lotion/ Cream Tripelennamine Cream Phendiamine Cream APPENDIX II Relative Potency of Selected Topical Corticosteroid Drug ProductsDosage Form Strength I. Very high potency Augmented betamethasone Ointment, Gel 0.05% dipropionate Clobetasol propionate Cream, Ointment 0.05% Diflorasone diacetate Ointment 0.05% Halobetasol propionate Cream, Ointment 0.05% II. High potency Amcinonide Cream, Lotion, 0.1% Augmented betamethasone Cream,Ointment Lotion 0.05% dipropionate Betamethasone Cream, Ointment 0.05% Betamethasonedipropionate valerate Ointment 0.1% Desoximetasone Cream, Ointment 0.25% Gel 0.05% Diflorasone diacetate Cream, Ointment 0.05% (emollient base) Fluocinonide Cream, Ointment, Gel 0.05% Halcinonide Cream, Ointment 0.1% Triamcinolone acetonide Cream, Ointment 0.5% III.
    [Show full text]
  • Cloderm® Cream (Clocortolone Pivalate 0.1%): a Moisturizing, Hydrating Formulation Enhances Epidermal Barrier Function
    CLINICAL INSIGHTS SUPPORTED BY PROMIUS PHARMA 2013, No. 2 Cloderm® Cream (clocortolone pivalate 0.1%): A Moisturizing, Hydrating Formulation Enhances Epidermal Barrier Function Leon Kircik, MD, FAAD It has been shown that application of some topical corti- DermResearch, PLLC, costeroids can increase TEWL and potentially contribute to Physicians Skin Care, PLLC, epidermal barrier dysfunction.6,7 In mice, application of topical Indiana University Medical Center, Indianapolis, IN, corticosteroids induced progressive increases in TEWL and a Mount Sinai Medical Center, New York, NY reduction in intercellular lipids in the SC.7 It is now well known The stratum corneum (SC) is a dynamic structure marked that even short-term use of topical corticosteroids can com- by multiple complex interactions and feedback loops.1-4 Self- promise epidermal barrier function and SC integrity by inhibit- repair of the permeability barrier has been documented; i.e., the ing epidermal lipid synthesis.8 However, certain formulations of SC can quickly adapt and initiate natural physiologic recovery. topical corticosteroids have been shown to improve skin hydra- Dysfunction of the SC is associated with specific disease states, tion and reduce TEWL.9,10 Perhaps the beneficial or detrimental perhaps most notably atopic dermatitis (AD), but also rosacea, effects of a given topical corticosteroid on TEWL have less to do psoriasis, and other inflammatory cutaneous disorders. More with the corticosteroid itself than with the vehicle in which it precisely, researchers and clinicians believe that AD may be is delivered.11 Thus, treatment becomes an act of balancing the driven in part by poor epidermal barrier function, perhaps as negative effects of the corticosteroid molecule itself on epider- a result of impairments in the permeability, immune response, mal barrier versus the positive impact of the vehicle that deliv- and antimicrobial barriers.
    [Show full text]
  • Appendix 6 – Characteristics and Safety Data from the Included Studies
    BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance Supplemental material placed on this supplemental material which has been supplied by the author(s) BMJ Open Appendix 6 – Characteristics and safety data from the included studies How safe are topical corticosteroids compared to emollient or vehicle? Study ID Study design and Intervention and Participants Cutaneous adverse events Systemic adverse events Unspecified adverse events (Systematic study duration comparator review*) (Quality assessment) Very potent topical corticosteroids Breneman 2003 RCT Intervention: Clobetasol Severity: moderate Local application site skin Unspecified adverse events (1) propionate 0.05% lotion (twice a to severe reactions Incidence comparable between 2 weeks treatment, then day) (n=96) No clinically significant groups. (unpublished) followed up for Age: ≥ 12 years telangiectasia or skin thinning additional 2 weeks Intervention: Clobetasol Treatment-related adverse (Feldman 2005 Sample size: 229 propionate 0.05% emollient events (2) Nankervis (3)) Cochrane risk of bias tool: participants cream (twice a day) (n=100) Clobetasol lotion = 4/96 patients randomisation described, (4.2%); Clobetasol cream = 1/100 allocation concealment Comparator: Vehicle (n=33) patients (1%) unclear, intention-to- Vehicle = 6/33 patients (18.2%) treat unclear. (Difference between groups: p= 0.0006a) Kimball 2008 (4) RCT Intervention: Clobetasol Severity: not Incidence of adverse events or (trial a) propionate emulsion specified in the treatment related adverse Duration not specified in formulation foam 0.05% review events (Frangos 2008 review Clobetasol foam = 8% (5)) Comparator: Vehicle Age: not specified in Risk of bias not assessed Vehicle foam = 10% the review in any of the included (no significant differences systematic reviews.
    [Show full text]
  • LGC Standards Pharmacopoeial Reference Standards 2014
    LL CTS INKSP RODUTO A L P ITH W WEBSHO LGC Standards Pharmacopoeial reference standards 2014 FOR STANDARDS WITH CofA SEE OUR CATALOGUE: PHARMACEUTICAL IMPURITIES AND PRIMARY REFERENCE STANDARDS LGC Quality – ISO Guide 34 • GMP/GLP • ISO 9001 • ISO/IEC 17025 • ISO/IEC 17043 Pharmaceutical impurities Code Product CAS No. CS Price Unit Adiphenine Hydrochloride O LGC Standards N O MM1172.00 Adiphenine Hydrochloride 50-42-0 A 250mg HCl Pharmaceutical impurities and Adrenaline Tartrate OH H OH O OH primary reference standardsMM0614.00 2014 N OH Adrenaline Tartrate 51-42-3 A 500mg OH OH O OH OH H MM0614.02 L-Adrenaline 51-43-4 A 500mg OH N OH Imp. C (EP) as Hydrochloride: 1-(3,4-Di- O H OH MM0614.13 hydroxyphenyl)-2-(methylamino)ethanone 62-13-5 A 100mg N HCl Hydrochloride (Adrenalone Hydrochloride) OH (1R)-1-(3,4-Dihydroxyphenyl)-2- OH O S O MM0614.01 methylaminoethanesulphonic Acid H 78995-75-2 A 100mg OH N (Adrenaline -Sulphonate) OH Alanine NH2 MM0566.00 Alanine 56-41-7 A 500mg OH O Imp. A (Pharmeuropa): (2 S)-2-Aminobutanedioic Acid O NH 2 MM0567.00 OH (Aspartic Acid) 56-84-8 A 500mg OH O Albendazole O H MM0382.00 Albendazole N O 54965-21-8 A 500mg N H S N Imp. A (EP): 5-(Propylsulphanyl)-1H- H MM0382.01 N 80983-36-4 A 100mg NH2 benzimidazol-2-amine S N O H Imp. B (EP): Methyl [5-Propylsulphinyl)- N O MM0382.02 N 54029-12-8 A 100mg H 1H-benzimidazol-2-yl]carbamate S N O O H Imp.
    [Show full text]
  • PA Drug Name Generic Name PA Summary Name Epaned Enalapril
    Prior Authorization Drug Criteria Cross Reference PA Drug Name Generic Name PA Summary Name Epaned enalapril ACE Inhibitors and Combinations Perindopril perindopril ACE Inhibitors and Combinations Prestalia perindopril/amlodipine ACE Inhibitors and Combinations Qbrelis lisinopril ACE Inhibitors and Combinations Trandolapril/Verapamil ER by Greenstone trandolapril/verapamil ER ACE Inhibitors and Combinations Acanya clindamycin/benzoyl peroxide Acne and Rosacea Agents, Topical Aczone dapsone Acne and Rosacea Agents, Topical Altreno, Avita, Tretinoin, Retin-A Micro tretinoin Acne and Rosacea Agents, Topical Azelex, Finacea azelaic acid Acne and Rosacea Agents, Topical Clindamycin, Clindacin, Evoclin clindamycin Acne and Rosacea Agents, Topical Clindamycin 1%/Benzoyl Peroxide 5%, Neuac clindamycin/benzoyl peroxide Acne and Rosacea Agents, Topical Kit, Onexton Differin, Adapalene adapalene Acne and Rosacea Agents, Topical Epiduo, Epidue Forte adalpalene/benzoyl peroxide Acne and Rosacea Agents, Topical Ery Pad, erythromycin pad erythromycin Acne and Rosacea Agents, Topical Erythromycin/Benzoyl Peroxide erythromycin/benzoyl peroxide Acne and Rosacea Agents, Topical Metrogel, Metronidazole, Noritate, Rosadan metronidazole Acne and Rosacea Agents, Topical Fabior, Tazorac tazarotene Acne and Rosacea Agents, Topical Soolantra ivermectin Acne and Rosacea Agents, Topical Ziana tretinoin/clindamycin Acne and Rosacea Agents, Topical BPO Cloths benzoyl peroxide Acne and Rosacea Agents, Topical BP 10-1%, Sulfacetamide Sodium/Sulfur, sodium sulfacetamide/sulfur
    [Show full text]
  • Pequot Health Care Steps Program* Updated Oct 2021 *Enrollment in Steps Program Varies on Health Plan Sponsor
    Pequot Health Care - Pequot Pharmacuetical Network (PRxN) Pequot Health Care Steps Program* Updated Oct 2021 *Enrollment in Steps program varies on health plan sponsor. Member benefits and client contract will prevail. If you have que stions or need further assistance after consulting this table, call our Pharmacy Benefits number or the number on the back of your insurance card. Providers call 888-779-6638 for Authorization Form. Program effective 1-2014; Updated 9-2015, 10-2015, 1-2016, 3-2016, 10-2016, 01-2017, 04-2017, 7-2017, 02-2018, 04-2018, 05-2018, 08-2018, 11-2018, 4-2019, 6-2019, 9-2019, 12-2019, 4-2020, 6-2020, 10-2020, 1-2021, 7-2021, 10-2021 THERAPEUTIC DRUGS INCLUDED IN PROGRAM PREREQUISITE DRUGS CATEGORY (TARGET DRUGS) ALLERGY Previous use of one of the following generics either alone or as a Antihistamine Clarinex, Clarinex-D, Semprex, Xyzal component of a combination product: fexofenadine, levocetirizine, loratadine or cetirizine Acular and Acular LS (brand), Acuvail, Alocril, Alomide, Bepreve, Cromlon (brand), Elestat (brand), Emadine, Lastacraft, Optivar azelastine, cromolyn sodium, epinastine, ketotifen (rx-only), ketorolac Eye Drops (brand), Patanol (brand), Pazeo (brand and generic 0.7%), Pataday 0.4% and 0.5%, olopatadine 0.1% (brand and generic 0.2%), Zerviate (brand) Allergy Reaction AuviQ EpiPen Inhaled Nasal Beconase AQ, Dymista, Flunisolide, Nasonex, Omnaris, Qnasl, Previous use of the following generic: fluticasone nasal inhaler Steroids Rhinocort Aqua, Xhance, Zetonna ANTI-INFECTIVE Adoxa, Avidoxy, Doyxyxline
    [Show full text]
  • Preferred Drug List (PDL)
    Preferred Drug List (PDL) Washington – Apple Health Effective Date: 7/1/2021 © 2021 United HealthCare Services, Inc. All Rights Reserved. UnitedHealthcare Community Plan complies with all Federal civil rights laws that relate to healthcare services. UnitedHealthcare Community Plan offers healthcare services to all members without regard to race, color, national origin, age, disability, or sex. UnitedHealthcare Community Plan does not exclude people or treat them differently because of race, color, national origin, age, disability, or sex. This includes gender identity, pregnancy and sex stereotyping. UnitedHealthcare Community Plan also complies with applicable state laws and does not discriminate on the basis of creed, gender, gender expression or identity, sexual orientation, marital status, religion, honorably discharged veteran or military status, or the use of a trained dog guide or service animal by a person with a disability. If you think you were treated unfairly because of your sex, age, race, color, disability or national origin, you can send a complaint to: Civil Rights Coordinator UnitedHealthcare Civil Rights Grievance P.O. Box 30608 Salt Lake City, UTAH 84130 [email protected] You can call or write us about a complaint at any time. We will let you know we received your complaint within two business days. We will try to take care of your complaint right away. We will resolve your complaint within 45 calendar days and tell you how it was resolved. If you need help with your complaint, please call 1-877-542-8997, TTY 711, Monday through Friday, 8:00 a.m. to 5:00 p.m. You can also file a complaint with the U.S.
    [Show full text]
  • Wo 2008/127291 A2
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date PCT (10) International Publication Number 23 October 2008 (23.10.2008) WO 2008/127291 A2 (51) International Patent Classification: Jeffrey, J. [US/US]; 106 Glenview Drive, Los Alamos, GOlN 33/53 (2006.01) GOlN 33/68 (2006.01) NM 87544 (US). HARRIS, Michael, N. [US/US]; 295 GOlN 21/76 (2006.01) GOlN 23/223 (2006.01) Kilby Avenue, Los Alamos, NM 87544 (US). BURRELL, Anthony, K. [NZ/US]; 2431 Canyon Glen, Los Alamos, (21) International Application Number: NM 87544 (US). PCT/US2007/021888 (74) Agents: COTTRELL, Bruce, H. et al.; Los Alamos (22) International Filing Date: 10 October 2007 (10.10.2007) National Laboratory, LGTP, MS A187, Los Alamos, NM 87545 (US). (25) Filing Language: English (81) Designated States (unless otherwise indicated, for every (26) Publication Language: English kind of national protection available): AE, AG, AL, AM, AT,AU, AZ, BA, BB, BG, BH, BR, BW, BY,BZ, CA, CH, (30) Priority Data: CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, 60/850,594 10 October 2006 (10.10.2006) US ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, (71) Applicants (for all designated States except US): LOS LR, LS, LT, LU, LY,MA, MD, ME, MG, MK, MN, MW, ALAMOS NATIONAL SECURITY,LLC [US/US]; Los MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, Alamos National Laboratory, Lc/ip, Ms A187, Los Alamos, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, NM 87545 (US).
    [Show full text]
  • Texas Children's Hospital Dermatology Service PCP Referral Guidelines- Seborrheic Dermatitis
    Texas Children's Hospital Dermatology Service PCP Referral Guidelines- Seborrheic Dermatitis Diagnosis: SEBORRHEIC DERMATITIS GENERAL INFORMATION: • Seborrheic dermatitis is a common, benign skin condition that is thought to be caused by overgrowth of a yeast that resides on the skin, Malassezia. • In infants, this typically resolves within the first year of life, so treatment is not required. • In children and teenagers, this may be chronic, requiring maintenance therapy. TREATMENT RECOMMENDATIONS: For children/teenagers: Scalp: • Maintenance shampoo 2-3 times weekly (or less frequently for drier hair types), shampoo should be allowed to sit for ~5 minutes before rinsing) o Ketoconazole 2% shampoo o OTC Selenium sulfide shampoos (Selsun Blue, Head and Shoulders Clinical Strength) o OTC Pyrithione zinc shampoos (Head and Shoulders Classic Clean) • For symptomatic relief: Fluocinolone 0.01% (Derma smoothe oil) or clobetasol 0.05% solution twice daily as needed. Face: • Miconazole 1 % cream (or other anti-yeast medication) mixed in equal amounts with hydrocortisone 2.5% cream (or other class 5, 6, 7 topical steroid) For infants with generalized skin involvement • Mild: Miconazole 1 % cream (or other anti-yeast medication) mixed in equal amounts with hydrocortisone 2.5% ointment (or other class 5, 6, 7 topical steroid) • Severe: Miconazole 1 % cream (or other anti-yeast medication) mixed in equal amounts with triamcinolone 0.1% ointment (or other class 3 or 4 topical steroid) REFERRAL GUIDELINES: Please refer patients who fail treatment guidelines above. Please avoid referring patients who are frustrated by need for maintenance therapy, as this is expected. Educational recommendations are made from the best evidence, expert opinions and consideration for the patients and families cared for by the service.
    [Show full text]
  • A Systematic Review of the Safety of Topical Therapies for Atopic Dermatitis J
    REVIEW ARTICLE DOI 10.1111/j.1365-2133.2006.07538.x A systematic review of the safety of topical therapies for atopic dermatitis J. Callen, S. Chamlin,* L.F. Eichenfield, C. Ellis,à M. Girardi,§ M. Goldfarb,à J. Hanifin,– P. Lee, D. Margolis,** A.S. Paller,* D. Piacquadio, W. Peterson, K. Kaulback,àà M. Fennerty– and B.U. Wintroub§§ Department of Dermatology, University of Louisville, Louisville, KY, U.S.A. *Department of Dermatology, Northwestern University’s Feinberg School of Medicine, Chicago, IL, U.S.A. Department of Dermatology, University of California San Diego, San Diego, CA, U.S.A. àDepartment of Dermatology, University of Michigan Medical School, Ann Arbor, MI, U.S.A. §Department of Dermatology, Yale University School of Medicine, New Haven, CT, U.S.A. –Department of Dermatology, Oregon Health and Science University, Portland, OR, U.S.A. **Departments of Dermatology and Gastroenterology, University of Pennsylvania School of Medicine, Philadelphia, PA, U.S.A. Department of Gastroenterology, University of Texas Southwestern Medical Center at Dallas, Dallas, TX, U.S.A. ààMedical Advisory Secretariat, Ministry of Health and Long Term Care, Toronto, ON, Canada §§Department of Dermatology, University of California San Francisco, 1701 Division Street, Room 338, San Francisco, CA 94143-0316, U.S.A. Summary Correspondence Background The safety of topical therapies for atopic dermatitis (AD), a common Bruce U. Wintroub. and morbid disease, has recently been the focus of increased scrutiny, adding E-mail: [email protected] confusion as how best to manage these patients. Objectives The objective of these systematic reviews was to determine the safety of Accepted for publication 9 June 2006 topical therapies for AD.
    [Show full text]